Voyager Therapeutics, Inc. (VYGR) analyst actions
Rating and price-target actions on VYGR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the VYGR overview →
2 measured VYGR analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 | Press release | -2.94% | -4.71% | |
| Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease | Press release | -1.45% | -5.33% |
Keep exploring
More VYGR: earnings → · SEC filings → · VYGR overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 321 | -0.14% | 45% |
| Pulse Biosciences, Inc (PLSE) | 320 | +0.18% | 55% |
| Viking Therapeutics, Inc. (VKTX) | 319 | -0.60% | 43% |
| Aptevo Therapeutics Inc. (APVO) | 318 | -0.89% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.